Cell Lines From High-Risk Breast Tissue
- Many risk factors for breast cancer have been identified, including family history, endocrine background, changes in breast tissue, cancer in one breast, radiation exposure, obesity and others. There is a spectrum of tissue changes seen in cancerous and pre-cancerous breast tissue.
- A cell line is a collection of cells that are grown in the laboratory from an original tissue specimen. Cell lines developed from high-risk breast tissue allow researchers to perform metabolic and molecular studies of breast cells over time.
Objective: To establish a repository (facility in which tissue samples can be preserved and stored for many years) of cell lines from high-risk breast tissue to allow researchers to learn more about changes in breast cells that may cause them to develop into breast cancer.
Eligibility: Women between 20 and 80 years of age who:
- Have an increased risk of breast cancer because they are members of a high-risk breast or ovarian cancer family.
- Have had breast cancer in one or both breasts.
- Have had radiation for lymphoma before the age of 30.
- Have a mutation in a breast cancer susceptibility gene, but whose family history is not known.
- Are not at increased risk of breast cancer.
- A small piece of breast tissue will be obtained from about 10 women without an identified risk of breast cancer and up to 100 women at high risk of developing breast cancer.
- Cell lines will be developed from each high-risk category.
- The cell lines and tissues will be used to establish a repository of high-risk breast cell lines and breast tissues that can be used to study how the cells develop into breast cancer.
|Official Title:||Establishment of Normal High Risk Breast Epithelial Cell Cultures, and A High Risk Cell Line and Tissue Repository From Breast Tissue From Women at High Risk of Breast Cancer|
|Study Start Date:||March 2002|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00032201
|United States, District of Columbia|
|Walter Reed Army Medical Center|
|Washington, District of Columbia, United States, 20301|
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||David N Danforth, M.D.||National Cancer Institute (NCI)|